Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Hold” by Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned a consensus recommendation of “Hold” from the eleven brokerages that are covering the stock, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $4.79.

A number of equities research analysts have issued reports on the company. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Royal Bank of Canada reduced their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. increased its position in shares of Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares in the last quarter. AQR Capital Management LLC grew its position in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the period. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth about $28,000. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth about $34,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Marinus Pharmaceuticals during the 1st quarter worth about $384,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Performance

Shares of Marinus Pharmaceuticals stock opened at $0.31 on Tuesday. Marinus Pharmaceuticals has a one year low of $0.26 and a one year high of $11.26. The stock’s fifty day moving average is $1.22 and its 200 day moving average is $1.31. The stock has a market cap of $17.00 million, a P/E ratio of -0.12 and a beta of 1.26.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.